- Home
- ORBS vs PRQR Comparison
ORBS vs PRQR Comparison
Compare ORBS & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ORBS | PRQR |
|---|---|---|
| Founded | 1966 | 2012 |
| Country | United States | Netherlands |
| Employees | 23 | 187 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.8M | 166.5M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | ORBS | PRQR |
|---|---|---|
| Price | $0.89 | $1.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.25 |
| AVG Volume (30 Days) | ★ 16.5M | 768.8K |
| Earning Date | 04-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $13.92 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.74 | $1.33 |
| 52 Week High | $15.96 | $3.10 |
Technical Indicators
Market Signals| Indicator | ORBS | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 48.77 | 46.00 |
| Support Level | $0.77 | $1.36 |
| Resistance Level | $1.33 | $2.10 |
| Average True Range (ATR) | 0.07 | 0.13 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 38.97 | 38.54 |
Price Performance
Historical ComparisonAbout ORBS Eightco Holdings Inc.
Eightco Holdings Inc operates in Forever 8 Inventory Cash Flow Solution. The company is a dynamic technology-focused company committed to driving growth and innovation through strategic acquisitions and management. Forever 8 focuses on purchasing inventory for e-commerce retailers and is part of its Inventory Solution Business.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.